Loading...
Tekla Life Sciences Investors
HQL•NYSE
Financial ServicesAsset Management
$12.79
$0.26(2.08%)
Tekla Life Sciences Investors (HQL) Financial Performance & Statements
Review Tekla Life Sciences Investors’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
268.50%
↑ 268.50%
Operating Income Growth
100.00%
↑ 100.00%
Net Income Growth
281.60%
↑ 281.60%
Operating Cash Flow Growth
0.00%
Operating Margin
-48.25%
↓ 48.25%
Gross Margin
100.00%
↑ 100.00%
Net Profit Margin
2143.14%
↑ 2143.14%
ROE
18.94%
↑ 18.94%
ROIC
-0.42%
↓ 0.42%
Tekla Life Sciences Investors (HQL) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for Tekla Life Sciences Investors stock.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $1.91M | $2.07M | $29.56M | $9.82M |
| Cost of Revenue | $0.00 | $0.00 | $2.59M | $2.65M |
| Gross Profit | $1.91M | $2.07M | $26.97M | $7.17M |
| Gross Profit Ratio | $1.00 | $1.00 | $0.91 | $0.73 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $3.18M | $2.72M | $0.00 | $1.44M |
| Operating Expenses | $3.18M | $2.72M | $38.42M | $15.94M |
| Total Costs & Expenses | $3.18M | $2.72M | $41.01M | -$23.98M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $1.27M | $653334.00 | $43812.00 | $470374.00 |
| EBITDA | $0.00 | $100.51M | -$11.45M | $34.27M |
| EBITDA Ratio | $0.00 | $48.67 | -$0.39 | $3.44 |
| Operating Income | -$1.27M | -$653336.00 | -$11.45M | $33.80M |
| Operating Income Ratio | -$0.66 | -$0.32 | -$0.39 | $3.44 |
| Other Income/Expenses (Net) | $36.31M | $50.91M | -$2985.00 | $1294.00 |
| Income Before Tax | $35.04M | $50.26M | -$11.45M | $33.80M |
| Income Before Tax Ratio | $18.30 | $24.33 | -$0.39 | $3.44 |
| Income Tax Expense | $0.00 | $0.00 | -$43812.00 | -$470374.00 |
| Net Income | $35.04M | $50.26M | -$11.45M | $33.80M |
| Net Income Ratio | $18.30 | $24.33 | -$0.39 | $3.44 |
| EPS | $1.22 | $1.84 | -$0.43 | $1.29 |
| Diluted EPS | $1.22 | $1.84 | -$0.43 | $1.29 |
| Weighted Avg Shares Outstanding | $28.77M | $27.35M | $26.79M | $26.21M |
| Weighted Avg Shares Outstanding (Diluted) | $28.77M | $27.35M | $26.79M | $26.21M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan